OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 61 - 70 of 695 studies

Cancer and neoplasms

Exploring the Molecular and Microenvironmental factors in Risk of monoclonal Gammopathy Evolution (EMERGE)

Myeloma is a treatable, but incurable, malignancy of plasma cells in the bone marrow (BM). It represents the final stage in a continuum of plasma cell disorders (PCDs) and is consistently preceded by a premalignant phase termed monoclonal gammopathy of undetermined significance (MGUS). MGUS therefore provides the opportunity to study how a premalignant condition progresses into cancer. MGUS-to-myeloma progression requires multiple genomic events and establishment of a permissive bone marrow microenvironment (BME). Historically, obtaining patient material to study MGUS has ...

GO TO STUDY Go

Cancer and neoplasms

Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (EVOLVE 2)

The proposed trial tests whether the addition of revumenib,compared to placebo,to azacitidine/venetoclax improves outcome in newly diagnosed adult patients with NPM1-mutated AML,who are not considered candidates for intensive chemotherapy by measuring overall survival. Newly diagnosed,previously untreated patients ≥18 years of age with NPM1-mutated or KMT2A-rearranged AML that are eligible for the study will be randomised in a 1:1 ratio to therapy with azacitidine/venetoclax with revumenib or placebo. Treatment will be on a continuous 28-day cycle schedule and continued until disease progression,development ...

GO TO STUDY Go

Cancer and neoplasms

Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy (EVOLVE-1 (HOVON 173))

The proposed trial test whether the addition of venetoclax,compared to placebo,with azacitidine and ivosidenib improves outcomes in newly diagnosed adult patients with IDH1 mutated AML,who are not considered candidates for intensive chemotherapy by measuring event free survival.. Newly diagnosed,previously untreated patients ≥18 years of age with IDH1-mutated or IDH1 mutated MDS/AML that are eligible for the study will be randomised in a 1:1 ratio to therapy with ivosidenib /azacitidine with venetoclax or placebo. Treatment will be on a continuous 28-day cycle ...

GO TO STUDY Go

Injuries and accidents

Randomised Evaluation of rehabilitation and Acute proximal Humerus fracture: a multi-centre, non-inferiority, randomised trial to compare the clinical and cost-effectiveness of a self-directed rehabilitation programme versus physiotherapist-supervised rehabilitation (usual care) for adults with a proximal humerus fracture

A break to the bone of the upper arm at the shoulder is a painful injury. It results in a sudden loss of use of the arm with recovery taking many months. Most injuries occur in people over 50 years of age after a fall, due to reduced bone strength, and are usually treated with a sling, although some fractures may need surgery. Currently, people are asked to see a physiotherapist a number of times to help with recovery after ...

GO TO STUDY Go

Generic health relevance

What is the feasibility and acceptability of conducting a randomised controlled trial evaluating a healthcare professional-supported, self-management intervention for people suffering from fatigue after critical illness?

AIM To explore if it is possible to carry out a study testing a fatigue self-management programme for people who survive an intensive care unit (ICU) admission. WHAT DO WE KNOW? Patients with life-threatening illness require care in an ICU. Approximately half of those who survive (approx. 82,000 per year) report fatigue lasting for a year or more. Fatigue is described as an overwhelming physical and mental exhaustion, not relieved by rest or sleep. Fatigue has a devastating impact on ...

GO TO STUDY Go

Metabolic and Endocrine

DETERMINING MINIMALLY INVASIVE ALTERNATIVES TO GLUCOSE, PROINSULIN AND C-PEPTIDE IN EARLY-STAGE TYPE 1 DIABETES

Type 1 diabetes (T1D) is a chronic disease, affecting around 1 in 350 children under the age of 15. Treatment is with life-long insulin and is typically started as an emergency when children present with dangerously high glucose (sugar) levels to their doctor. However, T1D has recognised stages before symptoms develop, providing an opportunity for early diagnosis, education and treatment before severe illness. Tests which help diagnose patients and tell doctors when a person may be soon need insulin ...

GO TO STUDY Go

Oral and Gastrointestinal

Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled, global clinical study to assess the efficacy, safety, tolerability and long-term clinical outcomes of pegozafermin administered once-weekly (QW) subcutaneously (SC), in approximately 762 subjects with compensated cirrhosis due to MASH (fibrosis stage F4 per NASH CRN criteria). The study schema is shown in Section 1.2. The study will enroll a broad spectrum of subjects with compensated cirrhosis, comprising those with or without CSPH. The study will enroll approximately 532 subjects with low ...

GO TO STUDY Go

Cancer and neoplasms

Pre-therapeutic MRI assessment of Early-Stage Rectal Cancer and Significant Rectal Polyps to avoid major resectional surgery (PRESERVE)

The PRESERVE trial aims to show that using our MRI reporting system we can substantially reduce the number of patients having major surgery for early rectal cancers (ERC). Bowel cancer is the UK’s third most common cancer. Major surgery removing a large section of bowel and surrounding tissue is routinely recommended as treatment for rectal cancer as per current guidelines. 1 in 5 patients require a permanent colostomy. It is widely reported by patients that their quality of life (QOL) ...

GO TO STUDY Go

Respiratory

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis (ASPIRE (VP-C21-011))

This is a randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either as monotherapy or on top of stable IPF therapy, are assessed in participants with IPF. The trial will include participants who are on stable licensed IPF therapy or who are currently not treated with a licensed IPF therapy. The latter group will include participants intolerant or not responsive to licensed IPF therapies, participants ineligible to receive these therapies and participants ...

GO TO STUDY Go

Inflammatory and immune system Mental health

IMPACT : Interventions to improve Mental health support in families with children and young people with Chronic RheumaTological conditions (IMPACT)

Background Paediatric Rheumatology is a term that covers over 80 conditions, affecting different parts of the body, such as Juvenile Arthritis. Children and young people (CYP) with rheumatological conditions can have high levels of mental health problems and therefore are at risk of poor health outcomes. We need to look at novel ways of providing early, essential support, to improve their current wellbeing. Our aims This study will create a digital-service that can guide parents through ways of supporting their CYP at ...

GO TO STUDY Go